Invitation to Infant Bacterial Therapeutics AB (publ) Capital Markets Day
Infant Bacterial Therapeutics welcomes representatives from the financial markets and media to our...
June 16, 2017
Annual General Meeting of Infant Bacterial Therapeutics AB (publ)
  The Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 4, 2017...
May 4, 2017

Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – March 31, 2017
Message from the CEO IBTs operations will during the current year be focused on completion of the...
May 4, 2017
Infant Bacterial Therapeutics AB (publ) Annual Report for 2016 has now been published
  Infant Bacterial Therapeutics AB (publ) Annual Report 2016 is now available on the...
April 6, 2017

Annual General Meeting of Infant Bacterial Therapeutics AB (publ)
Infant Bacterial Therapeutics AB (publ) will hold its Annual General Meeting at 2:00 p.m. on...
April 5, 2017
Infant Bacterial Therapeutics AB (publ), (IBT) has been approved for listing on Nasdaq First North’s Premier segment.
Infant Bacterial Therapeutics AB (publ) (“IBT”), today traded on Nasdaq First North, has...
March 10, 2017

IBT to present at Bio-Europe Spring 2017
Infant Bacterial Therapeutics AB (publ) (“IBT”), a pharmaceutical company that develops drugs...
March 1, 2017
Infant Bacterial Therapeutics AB (publ), (IBT) Interim report January 1 – December 31 2016
Message from the CEO “During the month of June, the first patients were recruited and dosed...
February 14, 2017

Last patient enrolled in IBT’s Phase 2 study
Infant Bacterial Therapeutics AB (publ) (“IBT”) announces that the last premature infant has...
January 24, 2017
IBT Corporate Presentation at the 9th Biotech Showcase
Find here the Corporate Presentation CEO Staffan Strömberg is presenting at the 9th Biotech...
January 11, 2017

IBT to present at 9th Annual Biotech Showcase 2017
  Infant Bacterial Therapeutics AB (publ) (“IBT”), a pharmaceutical company that...
December 15, 2016
IBT adds new indication for Gastroschisis-Related Intestinal Dysfunction
Infant Bacterial Therapeutics AB (publ) (“IBT”), a pharmaceutical company that develops drugs...
December 14, 2016

Positive recommendation from the independent Data Safety Monitoring Board to continue Phase II Study
  IBT announces that the second and last planned evaluation of safety data by the...
November 21, 2016
Infant Bacterial Therapeutics AB appoints new CFO
Infant Bacterial Therapeutics AB (publ.) (“IBT”) is pleased to announce the appointment of...
October 12, 2016

IBT welcomes new Business Analyst
IBT welcomes Crescent Yingyue Liao as Business Analyst. Crescent holds a Bachelor's degree in...
September 2, 2016
Infant Bacterial Therapeutics AB (publ), (IBT) Interim report January 1 – June 30 2016
  Message from the CEO “In June we announced that the first premature infant had been...
August 19, 2016

New Vice President Clinical Development at IBT
  IBT is welcoming Agneta Heierson as Vice President Clinical Development. She has over 25...
August 16, 2016
Infant Bacterial Therapeutics enrolls First Patient in Phase 2 Clinical Trial
  Infant Bacterial Therapeutics AB (publ) (“IBT”) announces that the first premature...
June 7, 2016

IBT’s rights issue fully subscribed
  The result of Infant Bacterial Therapeutics AB’s (“IBT” or the “Company”)...
May 26, 2016
Prospectus relating to IBT’s rights issue published
To access the press release, please read the following disclaimer here.
April 27, 2016

IBT announces fully underwritten SEK 100 million rights issue
To access the press release, please read the following disclaimer here.
April 27, 2016
IBT receives Rare Pediatric Disease Designation from FDA for drug candidate
Infant Bacterial Therapeutics AB (publ) (“IBT”) announces that the U.S. Food and Drug...
March 31, 2016

First day of trading of IBT B shares on NASDAQ First North
Today IBT rang the NASDAQ bell to start the first day of trading of IBT B shares on NASDAQ First...
March 29, 2016
Infant Bacterial Therapeutics is listed on Nasdaq First North and publishes company description
Infant Bacterial Therapeutics AB (publ) (“IBT”) has been approved for listing and the...
March 21, 2016

IBT welcomes a new Head of Pharmaceutical Development and Manufacturing
IBT is glad to welcome in its team Paul Alhadeff as Head of Pharmaceutical Development and...
March 14, 2016
Proposal for distribution and separate listing of Infant Bacterial Therapeutics from BioGaia
The board of directors of parent company BioGaia AB (publ) has resolved to propose to an...
February 19, 2016

IBT welcome new a Project Coordinator
IBT welcomes Jin-Yu Lu as Project Coordinator in Pharmaceutical Development. Jin has education in...
January 21, 2016
IBT has U.S. IND open and Swedish CTA approved for clinical study
IBT announces today that the IND (Investigational New Drug) for the prevention of necrotizing...
January 8, 2016

New CFO at IBT
Michael Owens has joined IBT as Chief Financial Officer. Michael has a background as Auditor at...
December 4, 2015
IBT has relocated to a new office
Come visit us at our new office at Bryggargatan 10, 111 21 Stockholm, Sweden.
October 1, 2015

New addition to IBT Board of Directors
Margareta Hagman, M.B.A, was elected to the Board of Directors in the beginning of...
September 24, 2015
IBT receives a further SEK 35 million funding from BioGaia
To support Infant Bacterial Therapeutics efforts to develop a drug to prevent the fatal disease...
September 7, 2015

IBT receives additional funding from BioGaia
Infant Bacterial Therapeutics plans to start a study on the safety and tolerability of the product...
March 26, 2015
Orphan Drug Designation in Europe
Infant Bacterial Therapeutics has now obtained the Orphan Drug Designation for Lactobacillus...
February 23, 2015

New Head of Clinical Operations at IBT
Infant Bacterial Therapeutics is glad to welcome Tina Lorentzon as Head of Clinical Operations....
February 2, 2015
New CCO at IBT
Sanjiv Sharma is joining Infant Bacterial Therapeutics as the new Chief Commercial Officer. Sanjiv...
November 7, 2014

New CTO at IBT
Infant Bacterial Therapeutics is appointing Anders Kronström as Chief Technical Officer. Anders...
October 20, 2014
New CMO at IBT
Infant Bacterial Therapeutics is welcoming Erik Kinnman as Chief Medical Officer. Erik will...
August 22, 2014

New board member at IBT
Anders Ekblom is the latest addition to the Board of directors at Infant Bacterial...
April 11, 2014
FDA approves orphan drug designation
Necrotizing enterocolitis (NEC) is a rare and extremely severe disease that affects premature...
February 21, 2014